Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated simtuzumab in combination with gemcitabine for metastatic pancreatic cancer, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Simtuzumab (simtuzumab)

Snippet

Sponsor: Gilead Sciences | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED